Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune

Grifols, a global leader in the production of plasma-derived medicines, has announced positive results from a Phase 4 study investigating the use of XEMBIFY®, its subcutaneous immunoglobulin product, administered every two weeks. The study successfully met its primary objective by demonstrating comparable levels of total immunoglobulins when compared to weekly administration in patients with pri..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 21.
  • textsms

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study for SerpinPC in Hemophilia B Treatment

16">The study aims to determine the effectiveness of SerpinPC in reducing bleeds in individuals with hemophilia B. Hemophilia B is a rare genetic disorder that affects the blood's ability to clot properly, leading to prolonged bleeding and increased risk of complications. Current treatment options for hemophilia B include regular infusions of clotting factors, but these can be costly and time-co..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 11.
  • textsms

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701

Inozyme Pharma, a clinical-stage rare disease biopharmaceutical company, has announced the dosing of the first infant with ENPP1 Deficiency in a Phase 1b trial of their drug, INZ-701. The trial, called ENERGY-1, aims to assess the safety and effectiveness of INZ-701 in infants with this condition. ENPP1 Deficiency is a progressive condition that can lead to severe symptoms and high mortality rat..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 28.
  • textsms